Colorectal cancer patients with liver metastases and severe hyperbilirubinemia: A consecutive series that explores the benefits and risks of chemotherapy by Walia, Tamana et al.
© 2008 Walia et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article 
which permits unrestricted noncommercial use, provided the original work is properly cited.
Therapeutics and Clinical Risk Management 2008:4(6) 1363–1366 1363
ORIGINAL RESEARCH
Colorectal cancer patients with liver metastases and 
severe hyperbilirubinemia:   A consecutive series that 
explores the beneﬁ  ts and risks of chemotherapy
Tamana Walia
J Fernando Quevedo
Timothy J Hobday
Gary Croghan
Aminah Jatoi
Division of Medical Oncology, 
Rochester, MN, USA
Correspondence: Aminah Jatoi
200 First Street SW, Rochester, Minnesota 
55905, USA
Email jatoi.aminah@mayo.edu
Background: Do colorectal cancer patients with hyperbilirubinemia and liver metastases 
beneﬁ  t from chemotherapy?
Methods/Results: This study entailed a review of 3,019 consecutive patients with colorectal 
cancer. Within this cohort, 20 met the study’s a priori selection criteria, which included a 
new diagnosis of colorectal cancer, no prior therapy, and a total bilirubin of 3.0 mg/dL. 
All 20 patients had liver metastases, and as a whole the group had a median serum bilirubin 
of 6.4 mg/dL (range 3.1, 28 mg/dL). Six patients received chemotherapy with an oxaliplatin-
containing regimen, and four subsequently sustained a drop in their bilirubin. In one instance, 
a drop from 27.2 to 2.5 mg/dL occurred. These six patients lived a median of 71 days (range 
23+, 283 days), but one treatment-related death occurred. In contrast, patients who received 
only supportive care lived a median of 28 days.
Conclusion: Chemotherapy appears to provide modest beneﬁ  t to newly diagnosed colorectal 
cancer patients with severe hyperbilirubinemia.
Keywords: colorectal cancer, liver metastases, hyperbilirubinemia, chemotherapy, 
oxaliplatin
Colorectal cancer is no longer considered a chemotherapy-resistant malignancy. A 1985 
study outlined the beneﬁ  ts of ﬁ  rst-line, single agent 5-ﬂ  uorouracil, describing tumor 
response rates of only 23% and a median survival of only 8.7 months (Burocker et al 
1985). No extra beneﬁ  ts were reported with the addition of other chemotherapy drugs 
(Burocker et al 1985).
Contrast these dismal results to more recent ﬁ  ndings. Goldberg and colleagues 
(2004) demonstrated that a multidrug, ﬁ  rst-line regimen, which consisted of oxaliplatin, 
leucovorin, and 5-ﬂ  uorouracil, yielded a tumor response rate of 45%, nearly double that 
reported earlier, and stretched the median survival by over two-fold, to 19.5 months. 
Such ﬁ  ndings underscore the major therapeutic strides that have occurred in the man-
agement of patients with metastatic colorectal cancer and demonstrate that this previ-
ously chemotherapy-resistant malignancy can now be viewed as chemosensitive.
Have such breakthroughs changed our approach? Are we now at the point where 
patients, who were formerly considered marginal candidates for chemotherapy, can be 
prescribed it routinely? Speciﬁ  cally, should patients with liver metastases and marked 
hyperbilirubinemia now be prescribed chemotherapy in the hope of improving their 
hepatic function and improving their clinical outcomes? To our knowledge, these 
questions have not yet been answered because large, prospective clinical trials typically 
require that patients enroll with normal or near-normal organ function. Moreover, to 
date, only small case reports, some of which are not totally relevant to the questions Therapeutics and Clinical Risk Management 2008:4(6) 1364
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posed above, have served to provide guidance on clinical 
management (Van Laethem et al 2003; Gupta et al 2007; 
Moosmann et al 2007). Hence, the purpose of the present 
study was to report outcomes within a group of colorectal 
cancer patients with severe hyperbilirubinemia presumably 
from liver metastases in an effort to provide more substantive 
guidance in answering the question of whether these patients 
beneﬁ  t from state-of-the-art chemotherapy.
Methods
Overview
The Mayo Clinic Institutional Review Board approved the 
study protocol prior to its implementation. The Mayo Clinic 
Tumor Registry then provided information on all patients 
seen at the Mayo Clinic in Rochester, Minnesota USA with 
a diagnosis of colorectal cancer between the years of 2002 
through 2006. The rationale for choosing 2002 as the start 
year rests in the fact that, by this time, oxaliplatin, an effec-
tive, non-liver metabolized drug, had been approved by the 
Food and Drug Administration for clinical use in colorectal 
cancer patients (Baldwin 2002).
Screening process of medical records
All medical records provided by the Tumor Registry were 
then screened by one investigator (TW) to identify patients 
who met the study team’s a priori selection criteria. These 
criteria included severe hyperbilirubinemia (deﬁ  ned below), 
unresectable metastatic colorectal cancer, and no prior 
colorectal cancer therapy (no prior surgery, radiation, or 
chemotherapy). With regard to the latter point, a deliberate 
decision was made to select colorectal cancer patients with a 
newly diagnosed malignancy, as those with recurrent disease 
were likely to tolerate chemotherapy poorly as a result of 
prior surgery, radiation, or chemotherapy, thereby potentially 
biasing conclusions negatively (Ho et al 1996; Petersen et al 
2007; Schneider et al 2007).
Severe organ dysfunction was initially deﬁ  ned on the 
basis of hyperbilirubinemia because of the proclivity of 
colorectal cancer to metastasize to the liver. Patients who 
had a serum total bilirubin of 3 mg/dL or greater in the 
absence of previous cancer therapy were the focus of this 
study. This threshold was chosen because another effective 
drug in colorectal cancer, irinotecan, is contraindicated at 
this serum bilirubin level for safety reasons (Schaaf et al 
2006), a fact that emphasizes the grave nature of this degree 
of hyperbilirubinemia. Thus, it appeared reasonable to target 
patients with this degree of organ dysfunction and to utilize 
this serum bilirubin threshold in the screening process.
In depth review of medical records
The medical records of patients identiﬁ  ed in this screening 
process were then reviewed in depth. One investigator (TW) 
reviewed these medical records, and another investigator (AJ) 
conﬁ  rmed speciﬁ  c information.
Information on patient age at cancer diagnosis, gender, 
relevant laboratory data, method of assessing the presence 
of liver metastases, whether liver metastases were in fact 
present, the number and type of chemotherapy regimens 
prescribed, whether a biliary stent was placed, adverse events, 
and overall survival were gleaned from each medical record. 
Tumor response was not assessed because of inconsistent 
patterns in radiographic testing from patient to patient and 
because of the greater value placed on survival (ASCO 1996; 
Therasse et al 2000). It was also decided not to attempt to 
glean information on performance status in view of incon-
sistent reporting and attribution from physician to physician 
(Sorensen et al 1993).
Data analyses
This study was intended to be descriptive; all demographic 
and outcome data are presented as such. Survival is deﬁ  ned 
as the interval between cancer diagnosis and date of death. 
In the event that the date of death was unknown, data were 
censored from the date of last follow up. JMP version 6 
(SAS Inc., Cary, NC) was used to construct Kaplan–Meier 
survival curves.
Results
Patient demographics
A total of 3,019 patients were initially identiﬁ  ed by the Mayo 
Clinic Tumor Registry. The vast majority was found to have 
a serum bilirubin 3 mg/dL and/or to have received prior 
cancer treatment. Nonetheless, the screening process yielded 
20 patients who met the selection criteria.
Among these 20 patients, 11 were male (55%), and the 
median age at colorectal cancer diagnosis was 54 years 
(range 39, 81) (Table 1). Only 2 had rectal cancer, and the 
remaining colon cancer. The median bilirubin level was 
6.4 mg/dL (range 3.1, 28 mg/dL). All had liver metastases, 
as seen by computed tomography (17 patients), ultrasound 
(1 patient), or surgical exploration or biopsy (2 patients). 
Hyperbilirubinemia was not attributable to hemolysis in any 
patient, and, in effect, review of the medical record did not 
show any apparent nonbiliary or nonhepatic cause.
Six patients received chemotherapy, and 12 received 
only supportive care. In two patients, the medical record did Therapeutics and Clinical Risk Management 2008:4(6) 1365
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not document chemotherapy administration or the decision 
to resort to supportive care exclusively, but one of these 
patients was alive at 394 days after diagnosis. In this patient, 
internal and external records show a recommendation to 
proceed with an oxaliplatin-based regimen in combination 
with bevacizumab. Well documented, ﬁ  rst-line chemotherapy 
in the other patients included: oxaliplatin, 5-ﬂ  uorouracil, 
and leucovorin (three patients); oxaliplatin, 5-ﬂ  uorouracil, 
leucovorin, and bevacizumab (one patient); and oxaliplatin 
and capecitabine (one patient). Second-line chemotherapy 
that consisted of irinotecan, 5-ﬂ  uorouracil, and leucovorin 
was administered to one patient.
The median survival of the six chemotherapy-treated 
patients was 71 days. Among the 12 nontreated patients, it 
was 28 days (Figure 1).
Chemotherapy and/or biliary stent placement was asso-
ciated with a drop in bilirubin in four patients (Table 2). 
Chemotherapy alone was associated with a decrease in 
bilirubin in two patients, leading to a decline from 27.7 to 
2.5 mg/dL in one and a modest decline from 6.5 to 5.7 mg/dL 
in another. It is impossible to say that this decline is deﬁ  nitely 
attributable to the chemotherapy. In ﬁ  ve patients, a stent was 
placed, and two of these patients also received chemotherapy. 
It appears that the nonstented patients had hepatic dysfunc-
tion related to intra-parenchymal liver disease. In one of 
these stented, chemotherapy-treated patients, the bilirubin 
dropped from 16.2 mg/dL to a normal level of 0.6 mg/dL; 
and, in the other, it dropped from 12.5 mg/dL to 3 mg/dL. In 
the three other patients who underwent only stent placement, 
the bilirubin stayed the same in one, increased in another, 
and apparently was not rechecked in the third.
In terms of adverse events, severe fatigue was noted in 
one patient who received chemotherapy. Another suffered 
from mucositis and dehydration after chemotherapy. 
This same patient was hospitalized and died from a 
gastrointestinal bleed approximately five weeks after 
receiving bevacizumab (Patient #2 in Table 2).
Discussion
To our knowledge, this study is one of the few to evaluate 
outcomes in colorectal cancer patients with liver metastases 
and severe hyperbilirubinemia. Overall, these 20 patients did 
poorly. None achieved the median survival of 19.5 months, as 
reported by Goldberg and colleagues (2004); and, in fact, only 
one was conﬁ  rmed to live beyond the one-year mark. The 
observations that patients who received chemotherapy lived 
relatively longer and at times manifested a decline in biliru-
bin suggest that chemotherapy was providing antineoplastic 
effects. Hence, a small subgroup of patients with colorectal 
cancer, liver metastases, and severe hyperbilirubinemia 
appears to derive modest beneﬁ  ts from chemotherapy.
It is important to point out the limitations of this study. 
First, patients who received chemotherapy may have been 
more ﬁ  t, better able to tolerate it, and therefore more likely 
to derive beneﬁ  t from it. In the absence of a randomized, 
controlled trial, the best we can conclude is that a subgroup of 
patients with hyperbilirubinemia appears to beneﬁ  t. It remains 
unclear whether chemotherapy provides better outcomes com-
pared to supportive care alone. Second, although this study 
observed that one patient did die from a chemotherapy-related 
complication, the retrospective design of this study might 
predispose to the underreporting of adverse events. Thus, we 
cannot claim that the risk to beneﬁ  t ratio of chemotherapy 
clearly justiﬁ  es its administration, despite the fact that the 
median survival was greater among chemotherapy-treated 
patients. Third, although it is tantalizing to conclude that 
perhaps patients with hyperbilirubinemia in the setting of 
other malignancies would also potentially benefit from 
Table 1 Baseline characteristics (n = 20)
Age (in years)
  Median (range) 54 (39, 81)
Gender
  Male (%) 11 (55)
  Female (%) 9 (45)
Serum bilirubin (in mg/dL)
  Median (range) 6.4 (3.1, 28)
Cancer site
  Colon (%) 18 (90)
  Rectum (%) 2 (10)
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Figure 1 Median survival among the chemotherapy-treated patients was 71 days (red 
line), and among nontreated patients 28 days (blue line).Therapeutics and Clinical Risk Management 2008:4(6) 1366
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Table 2 Outcomes among the nine chemotherapy-treated and/or stented patients
12 3 4 5 6 7 8 9
Age (years) 56 81 80 49 51 46 62 53 57
Gender Male Female Male Male Male Male Male Male Male
Total bilirubin at 
diagnosis (mg/dL)
16.2 27.7 13.8 6.2 4.4 3.5 12.5 6.5 3.2
Stent placement 
at diagnosis
Yes No Yes No Yes No Yes No Yes
Chemotherapy Oxaliplatin, 
5-ﬂ  uorouracil, 
Leucovorin,
then irinotecan, 
5-ﬂ  uorouracil, 
leucovorin
Oxaliplatin, 
5-ﬂ  uorouracil, 
Leucovorin, 
bevacizumab
None Oxaliplatin, 
capecitabine
None Oxaliplatin, 
5-ﬂ  uorouracil, 
Leucovorin,
Oxaliplatin, 
5-ﬂ  uorouracil, 
Leucovorin,
Oxaliplatin, 
5-ﬂ  uorouracil, 
Leucovorin, 
bevacizumab
Unknown
Drop in bilirubin? Yes Yes No No No No Yes Yes Unknown
Survival (days)* 283 59 86 24 23+ 46 170+ 71 394+
Note: *Censored data are denoted by a + sign.
chemotherapy, this conclusion would be perilous. Further 
study of hyperbilirubinemia in other cancer settings is indi-
cated before such conclusions can be drawn.
The question of whether or not to attempt to place a 
stent in patients with biliary obstruction also remains unan-
swered. This study included only two patients who had had 
a biliary stent placed and who did not receive subsequent 
chemotherapy. These two patients manifested little clinical 
improvement. Although no ﬁ  rm conclusions can be drawn, 
we might begin to question the value of stenting a patient in 
the absence of plans to initiate subsequent chemotherapy. 
This issue perhaps merits further study.
In summary, the present study provides justiﬁ  cation for 
prescribing chemotherapy to patients with colorectal cancer, 
liver metastases, and hyperbilirubinemia. However, given the 
poor outcome in this series as a whole, it remains prudent to 
continue to rely on clinical judgment in making therapeutic 
decisions and to discuss risks and beneﬁ  ts with patients and 
their families at length prior to prescribing chemotherapy.
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